NUPR1 and hepatocellular carcinoma: To explore the effect of NUPR1 inhibition on PD‐1 immunotherapy, we established subcutaneous HCC tumors using Hepa1‐6 cells and initiated intraperitoneal drug administration from day 3 (Figure 5G).